论文部分内容阅读
目的:探讨血清中CYFRA21-1、CA125和NSE三种肿瘤标志物在不同组织类型肺癌中的临床诊断价值。方法:采用电化学发光免疫分析(ECLIA)技术测定82例肺癌患者、16例肺良性疾病患者、40例健康人血清中的CYFRA21-1、CA125和NSE水平。结果:肺癌组的三种肿瘤标志物水平均高于肺良性疾病组和正常对照组(P<0.05)。其中血清中CYFRA21-1、CA125、NSE的敏感性分别为61.0%、51.2%、34.1%,三者联合检测的敏感性为85.4%。CYFRA21-1在鳞癌的敏感性最高为78.6%;CA125在腺癌的敏感性为75%;NSE在小细胞未分化癌敏感性最高为66.7%。结论:血清CYFRA21-1、CA125和NSE的检测,尤其是三项联合检测有助于临床对肺癌的诊断,并对组织分型有较高的参考价值。
Objective: To investigate the clinical value of serum CYFRA21-1, CA125 and NSE in the diagnosis of different types of lung cancer. Methods: The serum levels of CYFRA21-1, CA125 and NSE in 82 patients with lung cancer, 16 patients with benign lung disease and 40 healthy people were determined by ECLIA. Results: The levels of three tumor markers in lung cancer group were significantly higher than those in benign lung disease group and normal control group (P <0.05). The serum CYFRA21-1, CA125, NSE sensitivity were 61.0%, 51.2%, 34.1%, the combined detection of the three sensitivity was 85.4%. The highest sensitivity of CYFRA21-1 in squamous cell carcinoma was 78.6%; the sensitivity of CA125 in adenocarcinoma was 75%; and the highest sensitivity of NSE in small cell undifferentiated carcinoma was 66.7%. Conclusion: The detection of serum CYFRA21-1, CA125 and NSE, especially the three joint detection, are helpful to the clinical diagnosis of lung cancer and have high reference value for tissue typing.